Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Manager
-
Negotiable
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Medical Writer
-
Salary is DOE
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
